// Company Overview //
| Stock Name | 上海心瑋醫療科技股份有限公司 - B - H股 |
|---|---|
| Stock Code | 06609 |
| Company Full Name | 上海心瑋醫療科技股份有限公司 - B - H股 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事研發、制造及銷售神經介入及心臟醫療器械。 |
| Listing Date | 2021-08-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市張江高科技產業東區瑞慶路590號9幢南2層 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.heartcare.com.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Prospectus Date | 2021-08-10 |
|---|---|
| Offer Price | HK$ 171.00 / shares |
| Total Funds Raised | HK$ 564,471,000 |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 141.2 |
| First Day Change | -24.56% |
| First Day Volume | 2053800.0 |
| First Day Turnover | 281742000.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約45.3%或約459.7百萬港元預期將分配至我們的核心產品； 2、約39.9%所或約404.9百萬港元預期將分配至我們管線內的其他在研產品； 3、約4.8%或約48.7百萬港元用于為透過內部研究提升研發能力及持續擴充產品組合提供資金； 4、約10.0%或約101.5百萬港元預期將用作營運資金及一般企業用途。 |
|---|
// Underwriting Syndicate //
联席保荐人 (2)
高盛（亚洲）有限责任公司
中国国际金融香港证券有限公司
整体协调人 (2)
高盛（亚洲）有限责任公司
中国国际金融香港证券有限公司
联席账簿管理人 (3)
高盛（亚洲）有限责任公司
中国国际金融香港证券有限公司
富途证券国际（香港）有限公司
联席牵头经办人 (3)
高盛（亚洲）有限责任公司
中国国际金融香港证券有限公司
富途证券国际（香港）有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 23,324,400 HKD | — | 2.07% | — | 6 months | 2022-02-20 |
| 2 | Aspex Master Fund | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 3 | Boyu Capital Opportunities Master Fund | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 4 | Goldstream Healthcare Focus Fund SP | 23,324,400 HKD | — | 2.07% | — | 6 months | 2022-02-20 |
| 5 | Lake Bleu Prime Healthcare Master Fund Limited | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 6 | LYFE CAPITAL FUND III (DRAGON), L.P. | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 7 | Octagon Investments Master Fund LP | 77,745,150 HKD | — | 6.89% | — | 6 months | 2022-02-20 |
| 8 | Sage Partners Master Fund | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 9 | Superstring Capital Master Fund LP | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
| 10 | The Valliance Fund | 38,868,300 HKD | — | 3.44% | — | 6 months | 2022-02-20 |
// Directors & Management //
| Chairman | 王國輝 |
|---|---|
| Company Secretary | 張涵,歐陽偉 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 王國輝(29.2%);LYFE Capital Management Limited(13.64%) |
|---|
